Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells $222,312.06 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $222,312.06. Following the sale, the chief operating officer directly owned 20,679 shares of the company’s stock, valued at $1,929,971.07. The trade was a 10.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Mirum Pharmaceuticals Stock Down 1.8%

Shares of MIRM opened at $94.29 on Monday. The firm has a market cap of $4.85 billion, a P/E ratio of -109.64 and a beta of 0.48. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $96.84. The firm’s 50-day simple moving average is $77.33 and its 200 day simple moving average is $70.90.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same quarter in the previous year, the company posted ($0.30) earnings per share. The business’s revenue was up 47.1% on a year-over-year basis. On average, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday. Raymond James Financial reaffirmed a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Citizens Jmp lifted their price objective on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, December 19th. Finally, Evercore ISI restated an “outperform” rating and set a $101.00 target price on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $102.58.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. MCF Advisors LLC grew its stake in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $33,000. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares in the last quarter. Quarry LP acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $41,000. Finally, CWM LLC increased its stake in Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.